BioSpace News Archive

Under the terms of the research collaboration agreement, CalciMedica will use EpiPharma’s state of the art Pre-clinical Drug Testing and Diagnostics Laboratory Platform to accelerate its drug discovery pipeline LA JOLLA, Calif. and SZEGED, Hungary and BUDAPEST, Hungary, July 21, 2020 (GLOBE NEWSWIRE) -- CalciMedica, a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, and EpiPharma, a

Financing intended to accelerate IND-enabling studies of allosteric drug candidates for rare genetic and neurodegenerative diseases, expand pipeline and support business development activities Eric I Richman appointed CEO and Director BETHESDA, Md., July 21, 2020 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (“Gain”) a biotechnology company focused on developing first-in-class medicines that target novel allosteric binding sites on enzymes for the treatment of rare genetic and CNS d

Guardant Health, Inc. announced it will report financial results for the second quarter 2020 after market close on Thursday, August 6, 2020.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Thomas Kochy joined the company as vice president, commercial and program strategy. In this newly created position, Mr. Kochy will be responsible for leading commercial planning, product strategy, and program management. This position will report into Adverum’s president, L

BetterLife Pharma Inc. has been a strong advocate and defender of using interferons as treatment for COVID-19, in particular as delivered through an inhalation device.

Ms. Pankovcin has 30 Years of Public Company Financial Experience with World Class Organizations

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to highlight an independent research study (the “Study”) from UT Dallas’ Center for Advanced Pain Studies, that identified Ifenprodil as one of a number of possible drug candidates for the treatment of COVID -19. The Study was recently published online on June 1,

On track to launch RAP device in 1H 2021 under COVID-19 Adjusted Commercialization Strategy

Genome Profiling and Fox Chase Cancer Center will collaborate to identify a novel immune system epigenetic biomarker, dubbed EpiMarker, which if successful, will be used to help predict which lung cancer patients are likely to respond to a checkpoint inhibitor therapy known as anti-PD1 antibody.

BioReference Laboratories, Inc., an OPKO Health company, announced that Geoff Monk, President of BioReference Laboratories, was recognized by CEO Today Magazine as one of this year’s 20 Healthcare Award winners.